Langer, Robert S.,Weight, Alisha K.,Larson, Alyssa M.,Klibanov, Alexander M.,Love, Kevin,Crane, Alan
申请号：
AU2020202407
公开号：
AU2020202407A1
申请日:
2020.04.06
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020202407A120200507.pdf#####ABSTRACT Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include lowmolecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.WO 2015/038818 PCT/US2014/055254 Viscositiesof biosimilar Erbitux with and without 0.25 NICSAL -- VIAL Jbklosmflar rbituNj., mghL FIG. 1 Viscosities of biosimilar Avastin with and without 0.25NI CSAL 50(40 .. .. ... . to 05 .200 200 300 IhisjninrvninmignxLstn FIG. 2
